Ovarian

Feasibility of Combined OvaRex (Oregovomab) Immunotherapy With Chemotherapy in Recurrent Ovarian Cancer

BC Shultes, AN Gordon, CF Nicodemus

AACR 2003, Abstract #3846

Immunization of advanced ovarian cancer patients with Mab-B43.13

T Ehlen, CF Nicodemus, J Pankovich, K Conlon, W Korz, J Berek

ASH 1999, Abstract #3384

A Randomized Phase II Study Assessing an Optimized Schedule of Oregovomab (O) anti-CA125 Vaccination with Carboplatin Paclitaxel (CP) Relative to CP alone in Front line Treatment of Optimally Cytoreduced Stage III/IV Ovarian Cancer (EOC)

G Ferrandina, PS Braly, C Terranova, V Salutari, C Ricci, F Raspagliesi, D Lorusso, PB Panici, P Scollo, F Plotti, M Brewer, MW Method, RW Holloway, M Madiyalakan, CF Nicodemus, SL Pecorelli, G Scambia, R Angioli

ASCO 2017

Translational Correlates of Indirect Antibody Immunization Using Scheduled Combination Therapy with Carboplatin-Paclitaxel Plus Oregovomab: A Randomized Study

A Battaglia, A Fattorossi, R Angioli, G Scambia, CF Nicodemus, M Madiyalakan

ESGO 2017